Eye drop’s claim to replace glasses cost it the launch & sale nod. The controversy & safety concerns
Regulatory approval to Entod Pharma for PresVu, meant to treat presbyopia, was revoked as the firm marketed it as a ...
The Drugs Controller General of India (DCGI) has suspended approval for PresVu, the eye drop that stirred excitement with its claim to replace reading glasses. The drug regulator revoked the marketing ...
The Drug Controller General of India (DCGI) has suspended the licence for the eyedrop meant to reduce the need for reading glasses in people with Presbyopia. The licence of eyedrop PresVu, ...
On September 4, the drug regulator had asked for an explanation from the company for the claims it made in the press following which the drug-maker also submitted its response.
Drug regulator suspends manufacturing and selling of Entod pharma's eye drops over unapproved claims
The DCGI has halted the authorization given to Mumbai-based Entod Pharmaceuticals to produce and market its novel eye drops, citing the company's assertions that it can assist individuals with ...
PresVu has been suspended by the DCGI due to misleading marketing claims that the eye drops can "cure" near-sightedness.
In response to the various alleged misleading claims made by Entod Pharma in respect to its Opthalmologic product, Drugs ...
Entod Pharmaceuticals denies making false claims about their new PresVu eye drops and plans to challenge the suspension by ...
The company, which was aiming for an October launch in the Indian market, said that it will challenge the suspension in court ...
DCGI suspends Entod Pharma`s eye drop permission for presbyopia treatment due to unapproved claims. The company will ...
The company claims no unethical or false presentation of facts about Presvu, will challenge the order in court.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback